• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: CORDIS CORPORATION TRAPEASE PVCF FEM/JUG 55CM CSI FILTER, INTRAVASCULAR, CARDIOVASCULAR

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

CORDIS CORPORATION TRAPEASE PVCF FEM/JUG 55CM CSI FILTER, INTRAVASCULAR, CARDIOVASCULAR Back to Search Results
Model Number 466P306AU
Device Problem Complete Blockage (1094)
Patient Problem Obstruction/Occlusion (2422)
Event Date 10/19/2020
Event Type  Injury  
Manufacturer Narrative

Per the patient profile form (ppf), the patient reports that after trapease implantation ivc occlusion, numbness in the left foot, back pain and anxiety related to the filter occurred. Per the medical records, history includes diabetes, hypertension and chronic anemia. The indication for filter placement was right lower extremity swelling with deep vein thrombosis (dvt) and multiple bilateral pulmonary emboli (pe). A venocavogram located the renal veins and assessed the caliber of the ivc. The filter was successfully deployed in an infrarenal position. There were no reports of complications. Approximately twelve years and two months after implant, a ct scan reported the ivc is collapsed and occluded below the level of the ivc filter. There are bilateral collateral vessels which drain into the venous system above the level of the ivc. Incidental findings included a fatty liver, multiple areas of cortical thinning suggesting changes related to previous reflux or infection, small fat containing umbilical hernia and mild degenerative disc disease of the spine. The product was not returned for analysis. A review of the device history record revealed no anomalies during the manufacturing and inspection processes that can be associated with the reported complaint. The trapease vena cava filter is indicated for use in the prevention of recurrent pulmonary embolism (pe) via percutaneous placement in the vena cava for patients in which anticoagulants are contraindicated, anticoagulant therapy for thromboembolic disease has failed, emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced or for chronic, recurrent pulmonary embolism where anticoagulant therapy has failed, or is contraindicated. The purpose of a vena cava filter is to catch thrombus from the lower extremities as it travels along normal blood flow patterns up towards the heart. Blood clots and occlusive thrombosis within the filter and vasculature do not represent a device malfunction. Collateral circulation maybe related to the reported occlusion of the filter/ivc and is a known potential event following ivc filter implantation. Anxiety, numbness and pain do not represent a device malfunction and may be related to underlying patient related issues. Clinical factors that may have influenced the event include patient, pharmacological and lesion characteristics. Without procedural films or images for review the reported event(s) could not be confirmed. Given the limited information available for review at this time, there is nothing to suggest that the reported events are related to the design and manufacturing process of the device; therefore, no corrective action will be taken. Should additional information become available, the file will be updated accordingly.

 
Event Description

Per the medical records, the patient was reported to have a history of diabetes, hypertension and chronic anemia, and prior to the index procedure was admitted to the hospital for right lower extremity swelling. Evaluation showed that the patient had a right lower extremity deep vein thrombosis (dvt), and a computerized tomography (ct) pulmonary angiogram, revealed multiple bilateral pulmonary emboli (pe). The patient was started on anticoagulant therapy and ultimately consented to an inferior vena cava (ivc) filter given the risk of hemorrhage. The right groin was prepared and draped in usual, strict aseptic fashion and utilizing ultrasound guidance, the femoral vein was accessed with a micropuncture needle. A catheter was then advanced to the mid ivc and contrast was injected during digital subtraction filming of the abdomen in the frontal projection. The ivc filter delivery sheath was placed with its tip at the level of the entry of the renal veins. The ivc filter was deployed in an ideal position with its apex at the level of the entry the renal veins. An inferior venacavogram was performed at the conclusion of the procedure to confirm the position of the filter, demonstrating a widely patent inferior vena cava with no caval thrombi. The patient tolerated the procedure well. There were no reported complications. Approximately twelve years and two months after the filter was implanted, the patient underwent an abdominal computerized tomography (ct) scan indicated for filter evaluation. The scan reported an intrarenal inferior vena cava filter. The ivc is collapsed and appears to be occluded below the level of the ivc filter. There are bilateral collateral vessels which drain into the venous system above the level of the ivc. Incidental findings included a fatty liver, multiple areas of cortical thinning suggesting changes related to previous reflux or infection, small fat containing umbilical hernia and mild degenerative disc disease of the spine. According to the information received in the patient profile form (ppf), the patient reports occlusion, becoming aware of this event approximately twelve years and two months after the filter implantation, and further experienced numbness in the left foot, back pain and anxiety related to the filter.

 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameTRAPEASE PVCF FEM/JUG 55CM CSI
Type of DeviceFILTER, INTRAVASCULAR, CARDIOVASCULAR
Manufacturer (Section D)
CORDIS CORPORATION
14201 nw 60th avenue
miami lakes FL 33014 2802
Manufacturer (Section G)
CORDIS CORPORATION
14201 nw 60th ave
miami lakes FL 33014 2802
Manufacturer Contact
karla castro
14201 nw 60th ave
miami lakes, FL 33014-2802
7863138372
MDR Report Key11347745
MDR Text Key232516843
Report Number1016427-2021-04774
Device Sequence Number1
Product Code DTK
Combination Product (Y/N)N
Reporter Country CodeUS
PMA/PMN NumberK020316
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type OTHER
Reporter Occupation
Type of Report Initial,Followup
Report Date 03/03/2021
1 Device Was Involved in the Event
1 Patient Was Involved in the Event
Date FDA Received02/19/2021
Is This An Adverse Event Report? Yes
Is This A Product Problem Report? No
Device Operator HEALTH PROFESSIONAL
Device MODEL Number466P306AU
Device Catalogue Number466P306AU
Device LOT NumberR0408512
Was Device Available For Evaluation? No
Is The Reporter A Health Professional? No
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received02/24/2021
Was Device Evaluated By Manufacturer? Device Not Returned To Manufacturer
Date Device Manufactured04/28/2008
Is The Device Single Use? Yes
Is this a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient TREATMENT DATA
Date Received: 02/19/2021 Patient Sequence Number: 1
Treatment
COOK 0.035 NEWTON GUIDEWIRE; COOK 5F PIGTAIL; UNK MICROPUNCTURE NEEDLE
-
-